-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing
NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
NuCana (NASDAQ:NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the U.S. Food and Drug Administration (FDA) for Acelarin.
Acelarin is a treatment in development by NuCana for patients suffering from advanced biliary tract cancer. There's currently a Phase III study underway that covers using it as a first-line treatment for this use.
So what does that mean for NCNA stock? Fast track designation is handed out by the FDA to treatments aiming at serious conditions or unmet medical needs. With it, the review process of a drug can go much fast, which means getting to market sooner.
- 7 Risk-Averse Stocks to Buy for a Fortified Portfolio
Hugh Griffith, founder and CEO of NuCana, said this in the press release boosting NCNA stock higher today.
"We recently announced enrollment of 418 evaluable patients in our Phase III study, which is expected to enable the first interim analysis in the first half of 2022. This has the potential to allow for an accelerated approval of a new drug application (NDA) for Acelarin in the United States. With both Fast Track and Orphan Drug designations in place, we look forward to working closely with the FDA in our efforts to gain approval for Acelarin as the first approved front-line treatment option for patients with biliary tract cancer."
NCNA stock is seeing heavy trading on today's FDA news. As of this writing, some 78 million shares have changed hands. For perspective, the company's daily average trading volume is around 357,000 shares.
There's more stock market news to dive into below!
We've got all the latest coverage that traders need to know about today. Among that is what's affecting Meta Materials (NASDAQ:MMAT), SoFi (NASDAQ:SOFI), and Helbiz (NASDAQ:HLBZ) shares today. You can learn all about those stocks at the following links!
More Wednesday Stock Market News
- MMAT Stock: 9 Things to Know About the Latest Meta Materials Merger
- SOFI Stock: Why Is Reddit Favorite SoFi Stumbling Today?
- HLBZ Stock: Why Is Red-Hot Helbiz Plunging Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股市新闻、股票咨询和交易提示
NuCana (NASDAQ:NCNA) stock is surging higher on Wednesday after the company revealed fast track designation from the U.S. Food and Drug Administration (FDA) for Acelarin.
努卡纳纳斯达克股票代码:NCNA)周三股价飙升,此前该公司公布了美国食品和药物管理局(FDA)对Acelarin的快车道指定。
Acelarin is a treatment in development by NuCana for patients suffering from advanced biliary tract cancer. There's currently a Phase III study underway that covers using it as a first-line treatment for this use.
Acelarin是NuCana公司正在开发的一种治疗晚期胆道癌患者的药物。目前有一项第三阶段的研究正在进行中,该研究涵盖了将其作为这种用途的一线治疗方法。
So what does that mean for NCNA stock? Fast track designation is handed out by the FDA to treatments aiming at serious conditions or unmet medical needs. With it, the review process of a drug can go much fast, which means getting to market sooner.
那么,这对新华社的股票意味着什么?快速通道指定是由FDA颁发给针对严重疾病或未得到满足的医疗需求的治疗。有了它,药物的审查过程可以快得多,这意味着更快地进入市场。
- 7 Risk-Averse Stocks to Buy for a Fortified Portfolio
- 为强化投资组合买入7只规避风险的股票
Hugh Griffith, founder and CEO of NuCana, said this in the press release boosting NCNA stock higher today.
NuCana创始人兼首席执行官休·格里菲斯(Hugh Griffith)在新闻稿中说了这番话,推动NCNA股价今天走高。
"We recently announced enrollment of 418 evaluable patients in our Phase III study, which is expected to enable the first interim analysis in the first half of 2022. This has the potential to allow for an accelerated approval of a new drug application (NDA) for Acelarin in the United States. With both Fast Track and Orphan Drug designations in place, we look forward to working closely with the FDA in our efforts to gain approval for Acelarin as the first approved front-line treatment option for patients with biliary tract cancer."
我们最近宣布在我们的第三阶段研究中招募418名可评估的患者,预计将在2022年上半年进行第一次中期分析。这有可能加速批准Acelarin在美国的新药申请(NDA)。随着Fast Track和孤儿药物指定的到位,我们期待着与FDA密切合作,努力获得批准,将Acelarin作为胆道癌患者的第一个批准的一线治疗方案。“
NCNA stock is seeing heavy trading on today's FDA news. As of this writing, some 78 million shares have changed hands. For perspective, the company's daily average trading volume is around 357,000 shares.
今天FDA的新闻让NCNA的股票交易火爆。截至撰写本文时,已有约7800万股易手。相比之下,该公司的日均交易量约为35.7万股。
There's more stock market news to dive into below!
下面有更多的股市新闻值得一探!
We've got all the latest coverage that traders need to know about today. Among that is what's affecting Meta Materials (NASDAQ:MMAT), SoFi (NASDAQ:SOFI), and Helbiz (NASDAQ:HLBZ) shares today. You can learn all about those stocks at the following links!
今天交易员需要了解的最新消息我们都有。在这其中,有一点是有影响的元材料(纳斯达克股票代码:MMAT)SOFI(纳斯达克:SOFI),以及赫尔比兹(纳斯达克股票代码:HLBZ)今天的股票。你可以在下面的链接上了解所有关于这些股票的信息!
More Wednesday Stock Market News
更多周三股市新闻
- MMAT Stock: 9 Things to Know About the Latest Meta Materials Merger
- SOFI Stock: Why Is Reddit Favorite SoFi Stumbling Today?
- HLBZ Stock: Why Is Red-Hot Helbiz Plunging Today?
- MMAT股票:关于最新的Meta Material合并需要知道的9件事
- 索菲股票:为什么Reddit最受欢迎的SoFi今天步履蹒跚?
- HLBZ股票:为什么红火的Helbiz今天暴跌?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,威廉·怀特没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点,以InvestorPlace.com为准出版指南.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
除了最罕见的例外,InvestorPlace不会发布关于市值低于1亿美元或每天交易量低于10万股的公司的评论。这是因为这些“廉价股”经常是诈骗艺术家和市场操纵者的游乐场。如果我们对可能受我们的评论影响的低成交量股票发表评论,我们要求 InvestorPlace.com该书的作者披露了这一事实,并警告读者其中的风险。
Read More: Penny Stocks — How to Profit Without Getting Scammed
阅读更多信息: 细价股-如何在不上当的情况下获利
The post NCNA Stock: The Big Cancer Drug News Sending NuCana Skyrocketing appeared first on InvestorPlace.
NCNA股票:大型抗癌药物新闻让NuCana暴涨的帖子首先出现在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧